Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Immunohistochemical Evaluation of CON6D/B5: A New CD30 Monoclonal Antibody

Immunohistochemical Evaluation of CON6D/B5: A New CD30 Monoclonal Antibody Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Immunohistochemical Evaluation of CON6D/B5 A New CD30 Monoclonal Antibody Sean K. Lau, MD, Premi Thomas, MD, and Lawrence M. Weiss, MD lymphoma. Expression of CD30 has been subsequently Abstract: Immunohistochemical evaluation of CD30 expression demonstrated in various histologic types of non-Hodgkin is commonly performed in the assessment of hematopoietic lymphoma, most notably anaplastic large cell lym- disorders and germ cell tumors. A new monoclonal antibody, phoma. Most nonhematopoietic neoplasms do not con- CON6D/B5, directed against the CD30 antigen has become sistently express CD30, with the exception of embryonal 7,8 commercially available for use in formalin-fixed paraffin-embedded carcinoma. Given the selective distribution pattern of tissue samples. The performance characteristics of CON6D/B5 CD30 among human neoplasms, immunohistochemistry were tested and compared with the well-characterized mono- using CD30 antibodies has been extremely useful in the clonal CD30 antibody Ber-H2. Among the various neoplasms assessment of lymphoproliferative disorders and germ cell analyzed, there was complete concordance between the results of neoplasms. CON6D/B5 and Ber-H2 staining. Similar to Ber-H2, CON6D/ The first monoclonal antibody generated to detect B5 immunoreactivity was observed in all cases of classical the CD30 antigen was designated as Ki-1. The Ki-1 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

Immunohistochemical Evaluation of CON6D/B5: A New CD30 Monoclonal Antibody

Loading next page...
 
/lp/wolters-kluwer-health/immunohistochemical-evaluation-of-con6d-b5-a-new-cd30-monoclonal-pFdEsdTKle

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Wolters Kluwer Health
ISSN
1541-2016
DOI
10.1097/PAI.0b013e3181c81d31
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/appliedimmunohist by BhDMf5ePHKbH4TTImqenVA5KvPVPZ0P5BEgU+IUTEfzO/GUWifn2IfwcEVVH9SSn on 06/10/2020 RESEARCH ARTICLE Immunohistochemical Evaluation of CON6D/B5 A New CD30 Monoclonal Antibody Sean K. Lau, MD, Premi Thomas, MD, and Lawrence M. Weiss, MD lymphoma. Expression of CD30 has been subsequently Abstract: Immunohistochemical evaluation of CD30 expression demonstrated in various histologic types of non-Hodgkin is commonly performed in the assessment of hematopoietic lymphoma, most notably anaplastic large cell lym- disorders and germ cell tumors. A new monoclonal antibody, phoma. Most nonhematopoietic neoplasms do not con- CON6D/B5, directed against the CD30 antigen has become sistently express CD30, with the exception of embryonal 7,8 commercially available for use in formalin-fixed paraffin-embedded carcinoma. Given the selective distribution pattern of tissue samples. The performance characteristics of CON6D/B5 CD30 among human neoplasms, immunohistochemistry were tested and compared with the well-characterized mono- using CD30 antibodies has been extremely useful in the clonal CD30 antibody Ber-H2. Among the various neoplasms assessment of lymphoproliferative disorders and germ cell analyzed, there was complete concordance between the results of neoplasms. CON6D/B5 and Ber-H2 staining. Similar to Ber-H2, CON6D/ The first monoclonal antibody generated to detect B5 immunoreactivity was observed in all cases of classical the CD30 antigen was designated as Ki-1. The Ki-1

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: May 1, 2010

There are no references for this article.